ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

XOLAIR
Allergies
Asthma/COPD
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

XOLAIR Rx

Generic Name and Formulations:
Omalizumab 150mg/vial; pwd for SC inj after reconstitution; preservative-free.

Company:
Genentech and Novartis

Therapeutic Use:

Indications for XOLAIR:

Chronic idiopathic urticaria in symptomatic patients despite H1-antihistamine treatment.

Limitations Of use:

Not for treating other forms of urticaria.

Adult:

Dosing is not dependent on serum total IgE level or body weight. Give by SC inj over 5–10 seconds; max 150mg per inj site. 150mg or 300mg every 4 weeks. Reevaluate periodically.

Children:

Not established.

Warnings/Precautions:

History of anaphylaxis. Have medications for treating anaphylaxis available, monitor for at least 2 hours after inj; may have delayed reaction. Discontinue if severe hypersensitivity, fever or arthralgia/arthritis occurs. Elevated serum IgE levels may persist for up to 1 year after stopping therapy. Patients at risk of malignancy or geohelminth infections; monitor. Eosinophilic conditions. Avoid abrupt cessation of systemic or inhaled corticosteroids in allergic asthma. Pregnancy. Nursing mothers.

Pharmacological Class:

Antiasthmatic (IgE blocker).

Adverse Reactions:

Nausea, nasopharyngitis, sinusitis, upper RTI, viral upper RTI, arthralgia, headache, cough, serum IgE increase.

Note:

Enroll female patients in pregnancy exposure registry by calling (866) 4XOLAIR.

Generic Availability:

NO

How Supplied:

Single-use vial (5mL)—1

Indications for XOLAIR:

Moderate-to-severe persistent asthma in patients ≥6yrs of age with a (+) skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled by inhaled corticosteroids.

Limitations Of use:

Not for relief of acute bronchospasm or status asthmaticus. Not indicated for treatment of other allergic conditions.

Adults and Children:

<6yrs: not established. Base dose and frequency on baseline serum total IgE level and body weight; see full labeling. Give by SC inj over 5–10 seconds; max 150mg per inj site. ≥6yrs: 75–375mg every 2 or 4 weeks. Reevaluate periodically.

Warnings/Precautions:

History of anaphylaxis. Have medications for treating anaphylaxis available, monitor for at least 2 hours after inj; may have delayed reaction. Discontinue if severe hypersensitivity, fever or arthralgia/arthritis occurs. Elevated serum IgE levels may persist for up to 1 year after stopping therapy. Patients at risk of malignancy or geohelminth infections; monitor. Eosinophilic conditions. Avoid abrupt cessation of systemic or inhaled corticosteroids in allergic asthma. Pregnancy. Nursing mothers.

Pharmacological Class:

Antiasthmatic (IgE blocker).

Adverse Reactions:

Adults: arthralgia, leg/arm/general pain, fatigue, dizziness, fracture, pruritus, dermatitis, earache, serum IgE increase; Children: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, epistaxis.

Note:

Enroll female patients in pregnancy exposure registry by calling (866) 4XOLAIR.

Generic Availability:

NO

How Supplied:

Single-use vial (5mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs